A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics

Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01775514

Enrollment

32277

Registered

2013-01-25

Start date

2012-10-31

Completion date

2015-10-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma * Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer

Exclusion criteria

* Participants not living in the city or representative region of the study center

Design outcomes

Primary

Measure	Time frame
Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region	36 months
Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region	36 months
Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region	36 months
Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region	36 months
Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region	36 months

Secondary

Measure	Time frame
Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy)	36 months
Overall Survival (OS)	36 months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	36 months
Percentage of Participants With Family History of Cancer and Other Conditions	36 months
Percentage of Participants Categorized by Tumor Size	36 months
Percentage of Participants Categorized by Diagnostic Methods	36 months
Percentage of Participants With Metastasis	36 months
Percentage of Participants Categorized by Tumor Localization	36 months
Percentage of Participants With History of Another Primary Cancer	36 months
Percentage of Participants Categorized by Histopathology Diagnosis	36 months
Percentage of Participants Categorized by the Staging System	36 months
Percentage of Participants Categorized by Surgery Type	36 months
Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)	36 months

Countries

Turkey (Türkiye)

Outcome results